.ANALYSIS FEATURE.06 August 2024.
A huge randomized regulated trial with cisgender women highlights the difficulties of fidelity to a regular oral preexposure prophylaxis routine and shows that twice-yearly treatment of lenacapavir can maintain effective HIV avoidance levels over 6 months.